Current Report Filing (8-k)
January 15 2021 - 12:36PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
January 14, 2021
INNOVATION PHARMACEUTICALS
INC.
|
(Exact Name of
Registrant as Specified in Charter)
|
Nevada
|
|
001-37357
|
|
30-0565645
|
(State or Other
Jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of Incorporation)
|
|
File Number)
|
|
Identification No.)
|
301 Edgewater
Place - Suite 100 Wakefield,
Massachusetts
|
|
01880
|
(Address of Principal
Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (978)
921-4125
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
|
Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐
|
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
|
☐
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Securities registered under Section 12(b) of the Exchange Act:
none
Indicate by check mark whether the Registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
Registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 7.01. Regulation FD Disclosure
On January 14, 2021, Innovation Pharmaceuticals Inc. issued a press
release titled, Innovation Pharmaceuticals’ Brilacidin for
the Treatment of COVID-19 Receives FDA Fast Track
Designation.
A copy of each press release is furnished herewith as Exhibit 99.1.
The information in this Current Report on Form 8-K under Item 7.01,
including the accompanying press release, shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933, as
amended, except as shall be expressly set forth by reference to
such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
INNOVATION
PHARMACEUTICALS INC.
|
|
|
|
|
|
Dated: January 15, 2021 |
By: |
/s/ Leo
Ehrlich |
|
|
Name:
|
Leo Ehrlich |
|
|
Title: |
Chief Executive Officer |
|